Archives: Projects/Publication

OCT Baseline Predictors for Initial BCVA Response to Intravitreal anti-VEGF Treatment in Eyes with Diabetic Macular Edema. The CHARTRES study.

OCT Baseline Predictors for Initial BCVA Response to Intravitreal anti-VEGF Treatment in Eyes with Diabetic Macular Edema. The CHARTRES study.

OCT Baseline Predictors for Initial BCVA Response to Intravitreal anti-VEGF Treatment in Eyes with Diabetic Macular Edema. The CHARTRES study.

Santos AR, Costa M, Schwartz C, Alves D, Figueira J, Silva R, Cunha-Vaz J

Retina 0:1-10, 2017 [Epub ahead of print]

2017

Agreement between OCT-Leakage and Fluorescein Angiography to identify sites of alteration of the Blood-Retinal Barrier in Diabetes

Agreement between OCT-Leakage and Fluorescein Angiography to identify sites of alteration of the Blood-Retinal Barrier in Diabetes

Agreement between OCT-Leakage and Fluorescein Angiography to identify sites of alteration of the Blood-Retinal Barrier in Diabetes

Cunha-Vaz J, Santos T, Alves D, Marques I, Neves C, Soares M, Lobo C

Ophthalmolgy Retina 2017 [Epub ahead of print]. DOI: 10.1016/j.oret.2017.02.002

2017

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J

Ophthalmic Reserch DOI: 10.1159/000455235

2017

Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.

Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.

Protocol for a randomised, double-masked, sham-controlled phase 4 study on the efficacy, safety and tolerability of intravitreal aflibercept monotherapy compared with aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy: the ATLANTIC study.

Marques JP, Farinha C, Ângelo Costa M, Ferrão A, Nunes S, Silva R

BMJ Open. 2017 Aug 28;7(8):e015785. doi: 10.1136/bmjopen-2016-015785.

2017

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

Lorenz K, Scheller Y, Katharina B, Franz G, Katharina P, Felix B, Crusiefen C, Flach J, Gehring M, Peto T, Silva R, Tal Y, Pfeiffer

Lorenzo et al.Trials (2017);18:128. DOI: 10.11186 /s 1306-017-1861-3.

2017

Diabetic Retinopathy phenotypes of 1 progression to macular edema. Pooled analysis from 2 independent longitudinal studies of up to two years duration.

Diabetic Retinopathy phenotypes of 1 progression to macular edema. Pooled analysis from 2 independent longitudinal studies of up to two years duration.

Diabetic Retinopathy phenotypes of 1 progression to macular edema. Pooled analysis from 2 independent longitudinal studies of up to two years duration.

Cunha-Vaz J, Ribeiro L, Costa MÂ, Simó R and the EVICR.net

Investigative Ophthalmology & Visual Science August 2017, Vol.58, BIO206-BIO210. doi:10.1167/iovs.17-21780

2017

Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Proje

Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Proje

Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Proje

Eurocondor Consortium Ana Rita Santos, Luísa Ribeiro, Francesco Bandello, Rosangela Lattanzio, Catherine Egan, Ulrik Frydkjaer-Olsen, José García-Arumí, Jonathan Gibson, Jakob Grauslund, Simon P. Harding, Gabriele E. Lang, Pascale Massin, Edoardo Midena, Peter Scanlon, Stephen J. Aldington, Sílvia Simão, Christian Schwartz, Berta Ponsati, Massimo Porta, Miguel Ângelo Costa, Cristina Hernández, José Cunha-Vaz and Rafael Simó

Diabetes 2017 Sep;66 (9):2503-2510.

2017
https://doi.org/10.2337/db16-1453

Measurements of Retinal Fluid by OCT-Leakage in Diabetic Macular Edema. A Biomarker of Visual Acuity Response to Treatment.

Measurements of Retinal Fluid by OCT-Leakage in Diabetic Macular Edema. A Biomarker of Visual Acuity Response to Treatment.

Measurements of Retinal Fluid by OCT-Leakage in Diabetic Macular Edema. A Biomarker of Visual Acuity Response to Treatment.

Ana Rita Santos; Dalila Alves; Torcato Santos; João Figueira; Rufino Silva; José G. Cunha-Vaz

Retina 0:1, 2017

2017

Da Monitorização da Segurança dos Medicamentos para a Monitorização da Segurança dos Doentes: Um Eixo Estratégico para a Atividade dos Farmacêuticos

Da Monitorização da Segurança dos Medicamentos para a Monitorização da Segurança dos Doentes: Um Eixo Estratégico para a Atividade dos Farmacêuticos

Da Monitorização da Segurança dos Medicamentos para a Monitorização da Segurança dos Doentes: Um Eixo Estratégico para a Atividade dos Farmacêuticos

Batel Marques F

Revista Portuguesa de Farmacoterapia. Out 2017; 9(4):51-54.

2017
http://revista.farmacoterapia.pt/index.php/rpf/article/view/166

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of ILUVIEN® in chronic diabetic macular edema patients considered insufficiently responsive to available therapies (RESPOND).

Figueira J, Henriques J, Amaro M, Rosas V, Alves D, Cunha-Vaz J

Ophthalmic Research Published online DOI: 10.1159/000455235;

2017

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

A prospective, randomized, placebo-controlled, double-masked, three-armed, multicenter phase II/III trial for the Study of a Topic Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Gaucoma – the STRONG study: study protocol for a randomised Controlled Trial.

Lorenz K, Scheller Y, Katharina B, Franz G, Katharina P, Felix B, Crusiefen C, Flach J, Gehring M, Peto T, Silva R, Tal Y, Pfeiffer

Lorenzo et al.Trials (2017);18:128

2017

Comparison of diabetic retinopathy classification using fluorescein angiography and optical coherence tomography angiography.

Comparison of diabetic retinopathy classification using fluorescein angiography and optical coherence tomography angiography.

Comparison of diabetic retinopathy classification using fluorescein angiography and optical coherence tomography angiography.

Soares M, Neves C, Marques IP, Pires I, Schwartz C, Costa MÂ, Santos T, Durbin M, Cunha-Vaz J.

Br J Ophthalmol. 2017 Jan;101(1):62-68. doi: 10.1136/bjophthalmol-2016-309424.

2017

Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial.

Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial.

Development of a Normative Database for Multifocal Electroretinography in the Context of a Multicenter Clinical Trial.

Simão S, Costa MÂ, Sun JK, Cunha-Vaz J, Simó R; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR).

Ophthalmic Res. 2017;57(2):107-117. doi: 10.1159/000450958.

2017

Rastreio da Retinopatia Diabética. Importância do Sistema de Classificação Automática.

Rastreio da Retinopatia Diabética. Importância do Sistema de Classificação Automática.

Rastreio da Retinopatia Diabética. Importância do Sistema de Classificação Automática.

Ribeiro L, Oliveira CM, Neves C, Ramos JD, Ferreira H, Lobo C, Figueira J, Silva R, Cunha-Vaz J

In: Vilela MAP, Putz C, Dantas AM. Retina Clínica. Texto e Atlas. Rio de Janeiro, Cultura Médica, 2016, p.395-411. ISBN 978-85-7006-668-8

2016

Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat Harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis.

Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat Harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis.

Benefit-risk of therapies for relapsing-remitting multiple sclerosis: testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat Harm (NNTH) and the likelihood to be helped or harmed (LHH): a systematic review and meta-analysis.

Mendes D, Alves C, Batel Marques F.

CNS Drugs. 2016 Oct;30(10):909-29. doi:10.1007/s40263-016-0377-9.

2016
http://link.springer.com/article/10.1007%2Fs40263-016-0377-9

A systematic review of observational studies evaluating costs of adverse drug reactions.

A systematic review of observational studies evaluating costs of adverse drug reactions.

A systematic review of observational studies evaluating costs of adverse drug reactions.

Batel Marques F, Penedones A, Mendes D, Alves C.

Clinicoecon Outcomes Res. 2016 Aug 24;8:413-26. doi:10.2147/CEOR.S115689.

2016
https://www.dovepress.com/a-systematic-review-of-observational-studies-evaluating-costs-of-adver-peer-reviewed-article-CEOR

Differences in VigiBase reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Differences in VigiBase reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Differences in VigiBase reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.

Sagwa EL, Souverein Pc, Ribeiro I, Leufkens HG, Mantel-Teeuwisse AK.

Pharmacoepidemiol Drug Saf. 2016 Nov 20. doi:10.1002/pds.4125.

2016
http://onlinelibrary.wiley.com/doi/10.1002/pds.4125/abstract

Outcomes from the first 6 years of operation of the Central Portugal Pharmacovigilance Unit.

Outcomes from the first 6 years of operation of the Central Portugal Pharmacovigilance Unit.

Outcomes from the first 6 years of operation of the Central Portugal Pharmacovigilance Unit.

Batel Marques F, Penedones A, Mendes D, Alves C.

J Patient Saf. 2016 Dec 16. doi:10.1097/PTS.0000000000000273.

2016
http://pt.wkhealth.com/pt/re/lwwgateway/landingpage.htm;jsessionid=Ym2Q62vBJj17YlTnBZThzl2tzsCQTr1hSVXnpct56By06TNTfRKx!1080955772!181195628!8091!-1?sid=WKPTLP:landingpage&an=01209203-900000000-99555